Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13253MR)

This product GTTS-WQ13253MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13253MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4668MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ1046MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ1957MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ14236MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ10108MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ13314MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ33MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ14580MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW